Seres Therapeutics (MCRB) Misses Q2 EPS by 218c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($2.27), $2.18 worse than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Canaccord Upgrades Iluka Resources Ltd (ILU:AU) (ILKAF) to Buy
• Koninklijke Ahold Delhaize NV (AD:NA) (ADRNY) Placed on Negative Catalyst Watch at JPMorgan